ALNYLAM PHARMACEUTICALS, INC. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of -$89.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-06-30 was -$89.00K.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-12-31 was -$820.00K, a 151.60% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-09-30 was -$53.00K.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-06-30 was -$53.00K.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2025 was -$981.00K, a 165.57% decline from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2024 was $1.50M, a 9.93% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2023 was $1.66M.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$89.00K 10-Q · filed 2026-07-30 | -$178.00K 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | -$820.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$873.00K derived: sum of 2 quarters · filed 2026-02-12 | -$926.00K derived: sum of 3 quarters · filed 2026-07-30 | -$981.00K 10-K · filed 2026-02-12 |
| 2025-09-30 | -$53.00K 10-Q · filed 2025-10-30 | -$106.00K derived: sum of 2 quarters · filed 2026-07-30 | -$161.00K 10-Q · filed 2025-10-30 | |
| 2025-06-30 | -$53.00K 10-Q · filed 2026-07-30 | -$108.00K 10-Q · filed 2026-07-30 | ||
| 2024-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.56M derived: sum of 2 quarters · filed 2026-02-12 | $1.53M derived: sum of 3 quarters · filed 2026-02-12 | $1.50M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$30.00K 10-Q · filed 2025-10-30 | -$60.00K derived: sum of 2 quarters · filed 2025-10-30 | -$93.00K 10-Q · filed 2025-10-30 | |
| 2024-06-30 | -$30.00K 10-Q · filed 2025-07-31 | -$63.00K 10-Q · filed 2025-07-31 | ||
| 2023-12-31 | $1.66M 10-K · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |